UK Cancer Drugs Fund Reforms Get Cautious Welcome, But More Needed

11 Jul 2016

• By Sten Stovall

NHS England has issued new guidelines on how cancer drugs will be appraised and funded in the UK, including the operation of the controversial Cancer Drugs Fund (CDF), which is being replaced by a new fund controlled by the HTA NICE from the end of July this year.

NHS England has finalized and published new arrangements for commissioning cancer medicines - including the use of the Cancer Drugs Fund - addressing some of the concerns voiced during the run-up consultation period by charities, patient groups and the pharma industry.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Novartis Doubles Down On Push For Higher Drug Prices In Europe

01 May 2025

• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

29 Apr 2025

• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Soriot Cautions Europe Amid More US Expansion

29 Apr 2025

• By Kevin Grogan

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

24 Apr 2025

• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.